ATXS vs. VERV, KALV, APLT, TVTX, YMAB, AVTE, LRMR, ABUS, IGMS, and OCS
Should you be buying Astria Therapeutics stock or one of its competitors? The main competitors of Astria Therapeutics include Verve Therapeutics (VERV), KalVista Pharmaceuticals (KALV), Applied Therapeutics (APLT), Travere Therapeutics (TVTX), Y-mAbs Therapeutics (YMAB), Aerovate Therapeutics (AVTE), Larimar Therapeutics (LRMR), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), and Oculis (OCS). These companies are all part of the "pharmaceutical preparations" industry.
Verve Therapeutics (NASDAQ:VERV) and Astria Therapeutics (NASDAQ:ATXS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, community ranking, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.
97.1% of Verve Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Astria Therapeutics shares are owned by institutional investors. 19.3% of Verve Therapeutics shares are owned by insiders. Comparatively, 2.9% of Astria Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Astria Therapeutics has a net margin of 0.00% compared to Astria Therapeutics' net margin of -1,226.51%. Astria Therapeutics' return on equity of -37.35% beat Verve Therapeutics' return on equity.
Verve Therapeutics presently has a consensus price target of $33.00, suggesting a potential upside of 451.84%. Astria Therapeutics has a consensus price target of $22.50, suggesting a potential upside of 141.16%. Given Astria Therapeutics' higher possible upside, equities analysts plainly believe Verve Therapeutics is more favorable than Astria Therapeutics.
Verve Therapeutics has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Astria Therapeutics has a beta of 0.81, meaning that its stock price is 19% less volatile than the S&P 500.
Astria Therapeutics received 537 more outperform votes than Verve Therapeutics when rated by MarketBeat users. Likewise, 72.55% of users gave Astria Therapeutics an outperform vote while only 46.15% of users gave Verve Therapeutics an outperform vote.
Astria Therapeutics has lower revenue, but higher earnings than Verve Therapeutics. Astria Therapeutics is trading at a lower price-to-earnings ratio than Verve Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Verve Therapeutics had 11 more articles in the media than Astria Therapeutics. MarketBeat recorded 13 mentions for Verve Therapeutics and 2 mentions for Astria Therapeutics. Verve Therapeutics' average media sentiment score of 0.99 beat Astria Therapeutics' score of 0.60 indicating that Astria Therapeutics is being referred to more favorably in the news media.
Summary
Verve Therapeutics beats Astria Therapeutics on 9 of the 17 factors compared between the two stocks.
Get Astria Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATXS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ATXS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Astria Therapeutics Competitors List
Related Companies and Tools
